Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells 1,949 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 1,949 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the sale, the chief financial officer now owns 177,195 shares of the company’s stock, valued at approximately $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Collegium Pharmaceutical Trading Up 2.6 %

NASDAQ COLL traded up $0.75 on Monday, reaching $29.66. The company had a trading volume of 348,880 shares, compared to its average volume of 422,500. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The stock has a market cap of $933.87 million, a price-to-earnings ratio of 12.78 and a beta of 0.99. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock’s 50 day moving average is $30.78 and its 200-day moving average is $33.19.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Analyst Ratings Changes

COLL has been the subject of a number of research reports. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Friday, January 10th. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $43.60.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently made changes to their positions in COLL. New Age Alpha Advisors LLC bought a new stake in Collegium Pharmaceutical in the 4th quarter valued at $40,000. TD Private Client Wealth LLC lifted its holdings in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC acquired a new position in shares of Collegium Pharmaceutical during the third quarter worth about $72,000. KBC Group NV grew its holdings in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after buying an additional 982 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.